Results 51 to 60 of about 11,948 (164)

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO‐2b/3 and ALLEGRO‐LT Clinical Studies for Alopecia Areata

The Journal of Dermatology, EarlyView.
ABSTRACT Ritlecitinib is an oral JAK3/TEC family kinase inhibitor approved for individuals aged ≥ 12 years with severe alopecia areata. Here we report interim efficacy and safety results with ritlecitinib up to Month 24 in the Asian subpopulation from the ALLEGRO phase 2b/3 and ALLEGRO‐LT studies.
Rie Ueki, Masato Mizuashi, Kazutoshi Harada, Xingqi Zhang, Wenyu Wu, Wen‐Hung Chung, Ohsang Kwon, Xin Luo, Victoria Basey, Robert Wolk, Nanzhi Shi, Kayo Fujita, Yimeng Shen, Tomohiro Hirose   +13 more
wiley   +1 more source

Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective

Saudi Pharmaceutical Journal
Objectives: To perform a budget impact analysis (BIA) of the adoption of baricitinib for the management of alopecia areata (AA) by a Saudi public sector payer.
A. Alshahrani, S. Al-Aqeel, M. Alshahrani, S. Alqahtani, S.T. Alhawwashi, M.S. Al-Nasser, M. Zaitoun   +6 more
doaj   +1 more source

Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis

European Journal of Medical Research, 2023
Objectives Several clinical trials have evaluated the efficacy and safety of baricitinib in COVID-19 patients. Recently, there have been reports on critical patients, which are different from previous research results.
Jing Sun, Shufang Wang, Xin Ma, Qingqing Wei, Yujuan Peng, Ying Bai, Guobin Miao, Chang Meng, Peng Liu   +8 more
doaj   +1 more source

Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT The efficacy and safety of ritlecitinib, a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, have been demonstrated in the ALLEGRO phase 2b/3 trial that enrolled patients aged ≥ 12 years with alopecia areata (AA) and ≥ 50% scalp hair loss.
Akira Yuasa, Kazumasa Kamei, Shota Saito, Masashi Mikami, Tatsunori Murata, Samantha Kiyomi Kurosky, Ernest H. Law, Kouki Nakamura, Rie Ueki   +8 more
wiley   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro

Journal of Neuroinflammation, 2019
Background Since HIV-associated neurocognitive disorders (HANDs) occur in up to half of HIV-positive individuals, even with combined antiretroviral therapy (cART), adjunctive therapies are needed.
Christina Gavegnano, Woldeab B. Haile, Selwyn Hurwitz, Sijia Tao, Yong Jiang, Raymond F. Schinazi, William R. Tyor   +6 more
doaj   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs

RMD Open
Objective To compare the effectiveness of a strategy administering baricitinib versus one using TNF-inhibitors (TNFi) in patients with rheumatoid arthritis (RA) after conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) failure in a ...
Mart van de Laar, Tim Jansen, A Willemze, Y P M Goekoop-Ruiterman, Reinhard Bos, Eric-Jan Kroot, Celine J van de Laar, Martijn A H Oude Voshaar, Peter ten Klooster, Danyta I Tedjo, Grada A Versteeg   +10 more
doaj   +1 more source

Navigating through uncertainty—Experience from the UK national VEXAS MDT

British Journal of Haematology, EarlyView.
Summary The objective of this study was to describe the establishment, structure and influence of the United Kingdom national multidisciplinary team (MDT) for vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic (VEXAS) syndrome and to assess its clinical outputs and perceived value among participating clinicians.
Daniel Pietsch, Austin Kulasekararaj, Sinisa Savic, on behalf of VEXNET‐UK MDT, Adam Al‐Hakim, Tanya Basu, Catherine Cargo, Onima Chowdhry, James Galloway, Eiphyu Htut, Stephen Jolles, Arvind Kaul, Helen Lachmann, Calman A. MacLennan, Anoop Mistry, Elspeth Payne, James Poulter, Farzana Rahman, Manoj Raghavan, Rachel Tattersall, Roochi Trikha, Villyn Yong, Taryn Youngstein, Anna Babb, Celia Beynon, Sarah Bingham, Nuno Borges, Jenny Bosworth, Carlos Campani, Marian Chan, Shikha Chattree, Niall Conlon, Robert Corser, Elena Ganendra, Paraskevi Gkreka, William Gordon, Elisabeth Grey‐Davies, Joanna Haughton, Simona Huica, Pawel Kaczmarek, Alison Laing, Areti Makrygeorgou, Susanna Mathew, Jill Mccormick, Muhammad Mohsin, Vidhya Murthy, Sateesh Nagumantry, Ognjenka Savanovic‐Abel, Shaun Smale, Alex Sternberg, Rosemary Waller, Sarah Westbury   +51 more
wiley   +1 more source

Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations

International Journal of Dermatology, EarlyView.
A panel of 18 dermatologists participated in a three‐round Delphi‐based consensus process to generate a standardized framework for the diagnosis and management of alopecia areata (AA) in Asia Pacific. Recommendations focus on practicality and clinical relevance within the regional context.
Rodney Sinclair, Chao‐Chun Yang, Wen‐Hung Chung, Rachita Dhurat, Anil Ganjoo, Saranya Khunkhet, Jinran Lin, Anchala Parthasaradhi, Hyun‐Tae Shin, Kihyuk Shin, Poonkiat Suchonwanit, Kian Teo Tan, Jyh Jong Tang, Wenyu Wu, Felix Boon‐Bin Yap, Leona Yip, Angeline Yong, Cheng Zhou   +17 more
wiley   +1 more source